Filing Details
- Accession Number:
- 0001246360-14-003716
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-09-04 17:21:10
- Reporting Period:
- 2014-09-02
- Filing Date:
- 2014-09-04
- Accepted Time:
- 2014-09-04 17:21:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 911326 | Synageva Biopharma Corp | GEVA | Biological Products, (No Disgnostic Substances) (2836) | 561808663 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1532219 | Anthony Quinn | 33 Hayden Ave Lexington MA 02421 | Evp, Cmo & Head Of R&D | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-09-02 | 10,000 | $23.00 | 35,595 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-09-02 | 8,600 | $69.88 | 26,995 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-09-02 | 400 | $70.50 | 26,595 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-09-02 | 700 | $71.96 | 25,895 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-09-02 | 300 | $72.88 | 25,595 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2014-09-02 | 10,000 | $0.00 | 10,000 | $23.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 30,000 | 2021-12-20 | No | 4 | M | Direct |
Footnotes
- The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 26, 2013.
- The Stock Option granted the reporting person an option to purchase 50,000 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 12/20/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from $69.46 to $70.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from $70.47 to $70.55. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from $71.47 to $72.16. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from $72.69 to $73.04. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
Billionaire Hedge Funds
